Us2.ai is proud to have been featured in a scientific presentation at ESC Cardio-Oncology 2026, with research from the Royal Brompton Hospital's Cardio-Oncology Centre of Excellence validating the use of Us2.ai's AI echo software in a dedicated cohort of patients with cancer.
The presentation highlights how AI-powered echocardiographic analysis can deliver accurate, reproducible cardiac assessments in a cardio-oncology setting, including in clinically challenging subgroups such as patients with prior radiotherapy, pericardial effusion, and obesity. With cancer therapy-related cardiac dysfunction representing a growing clinical challenge, these findings support the integration of Us2.ai into routine cardio-oncology echocardiographic workflows.
Presentation featuring Us2.ai:
- Validation of a deep learning-based workflow for the interpretation of the echocardiogram in a cardio-oncology population — demonstrating strong agreement between Us2.ai and conventional echocardiography for LVEF assessment and high accuracy for detecting clinically relevant LV dysfunction across key cancer subgroups, including breast cancer, BMI above 30, patients with prior radiotherapy, and pericardial effusion. Read more →